Moran Wealth Management LLC purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 16,928 shares of the company's stock, valued at approximately $5,158,000. Moran Wealth Management LLC owned 0.06% of Medpace as of its most recent filing with the SEC.
A number of other institutional investors have also recently added to or reduced their stakes in MEDP. Sone Capital Management LLC acquired a new stake in Medpace during the 4th quarter worth $1,318,000. Charles Schwab Investment Management Inc. boosted its stake in Medpace by 1.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 201,046 shares of the company's stock worth $66,794,000 after purchasing an additional 2,142 shares during the last quarter. Orion Portfolio Solutions LLC boosted its stake in Medpace by 347.6% during the 4th quarter. Orion Portfolio Solutions LLC now owns 4,248 shares of the company's stock worth $1,411,000 after purchasing an additional 3,299 shares during the last quarter. Fundsmith LLP acquired a new stake in Medpace during the 4th quarter worth $42,372,000. Finally, Park Avenue Securities LLC boosted its stake in Medpace by 1.8% during the 1st quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock worth $838,000 after purchasing an additional 48 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.
Medpace Trading Up 1.3%
MEDP traded up $3.89 on Friday, hitting $310.69. The company had a trading volume of 677,983 shares, compared to its average volume of 372,612. The firm has a market cap of $8.93 billion, a P/E ratio of 23.72, a PEG ratio of 5.61 and a beta of 1.47. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The company's fifty day moving average price is $300.94 and its 200 day moving average price is $319.90.
Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. Medpace had a net margin of 19.31% and a return on equity of 54.36%. During the same period in the previous year, the firm earned $3.20 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.
Insiders Place Their Bets
In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the business's stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the sale, the director now directly owns 2,998 shares in the company, valued at $904,856.36. This represents a 36.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 20.30% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the stock. Barclays assumed coverage on shares of Medpace in a research note on Tuesday, June 24th. They set an "equal weight" rating and a $300.00 target price on the stock. Leerink Partners assumed coverage on shares of Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 target price on the stock. TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and lowered their target price for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. Truist Financial reduced their price target on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a report on Wednesday, April 23rd. Finally, William Blair reiterated a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Twelve equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Medpace presently has a consensus rating of "Hold" and an average price target of $344.82.
Read Our Latest Report on Medpace
About Medpace
(
Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Further Reading
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
